Ombudsman disagrees with EMA clinical trial data disclosure policy
This article was originally published in Scrip
The European Ombudsman has criticised the European Medicines Agency for turning down requests for access to certain clinical trial data on two anti-obesity drugs – orlistat (Roche's Xenical) and rimonabant (Sanofi-Aventis's Acomplia)– on the grounds of protecting drug companies' commercial interests.
You may also be interested in...
A UK regulator with the MHRA is concerned that bioanalytical laboratories are not being given enough time to do their job properly by drug companies under pressure to ensure their clinical trials remain on schedule.
The UK regulator is expecting a rise in amendments and deviations to ongoing clinical investigations of medical devices due to the COVID-19 pandemic and has issued advice on how companies should manage these.
Work and movement-related restrictions are affecting the ability of companies to provide a timely response to questions relating to their prequalification dossiers.